STAGE IIIC CUTANEOUS MELANOMA AJCC V7

This early-phase study tested a combination of two drugs—pembrolizumab (an immunotherapy) and ibrutinib (a targeted therapy)—in 20 people with advanced melanoma that could not be surgically removed. The main goal was to find the safest dose of ibrutinib when used with pembrolizum…

This study tested two different doses of the drug ipilimumab, either alone or combined with high-dose interferon, in 88 people with advanced melanoma that could not be removed by surgery. The goal was to see if the combination could delay cancer growth better than ipilimumab alon…

This large phase III study enrolled 1,673 patients with high-risk melanoma that had been removed by surgery. It compared two drugs—ipilimumab and high-dose interferon alfa-2b—to see which one better prevents the cancer from returning. The goal is to find a more effective treatmen…

This early-phase study tests a new way to fight advanced melanoma. Doctors take a patient's own immune cells (T-cells), modify them in a lab to resist a tumor-blocking signal (TGF-beta), and return them to the body along with a drug (IL-2) that boosts their activity. The goal is …

This early-phase trial studies the safety and best dose of two drugs—riluzole and sorafenib—given together to adults with advanced solid tumors or melanoma that has spread and is hard to treat. The goal is to see if the combination can slow or stop tumor growth. About 35 particip…

This early-phase trial tests the safety and best dose of two drugs—MK-2206 and hydroxychloroquine—given together to people with advanced solid tumors, melanoma, prostate, or kidney cancer. The goal is to see if blocking a process called autophagy can help kill more cancer cells. …

This study tested whether adding a drug called GM-CSF (sargramostim) to the immunotherapy ipilimumab helps people with advanced melanoma that cannot be removed by surgery. About 245 participants received either ipilimumab alone or ipilimumab plus GM-CSF. The main goal was to see …